CHONGQING, China, Oct. 9, 2024 /PRNewswire/ -- Hongqi Auto recently participated in the Automotive New Quality Productive Force Development Forum, showcasing its achievements in the brand exhibition area. As a premium automotive brand under FAW Group ("FAW"), Hongqi is dedicated to delivering exceptional products and services that meet the growing consumer demand for superior lifestyles and delightful travel experiences.
The four vehicles displayed at the forum—Hongqi EH7, Hongqi HS7 PHEV, Hongqi HS3 PHEV, and Hongqi HQ9 PHEV—highlight the brand's latest technological advancements and design innovations.
"In 2021, FAW embarked on a digital and intelligent transformation strategy. Our journey towards this transformation is anchored in overhauling our core business," said Men Xin, Vice President of FAW Hongqi Brand Operation Committee and General Manager of the System Digitalization Department. The next phase of the transformation focuses on developing an AI-powered large model application that covers research, production, supply, sales, and service, aiming for complete business restructuring. This initiative is expected to enhance employee skills, evolve the brand's business model, and significantly improve corporate efficiency.
FAW Hongqi's wholesale sales surpassed 201,500 units in the first half of 2024, a 42.6% year-on-year growth. Retail sales rose to 190,900 units, up 25% over the same period. Additionally, Hongqi's sales of electric vehicles (EVs) in 2023 exceeded 85,000 units, a remarkable 135% year-on-year increase.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Xinhua Finance: Hongqi Auto Participates in the Automotive New Quality Productive Force Development Forum
T. Rowe Price Investment Management, Inc. and Braidwell LP participate as new investors
Stephen Williams, MD, Ph.D. joins as Chief Scientific Officer
Rebecca Chambers and Frank Witney, Ph.D. appointed to Board of Directors
FREMONT, Calif., Jan. 12, 2026 /PRNewswire/ -- Alamar Biosciences, Inc. ("Alamar"), a leader in precision proteomics dedicated to advancing the early detection of disease, announced the close of an oversubscribed convertible notes financing, bringing in more than $50 million of new capital. Accounts advised by T. Rowe Price Investment Management, Inc. and Braidwell LP joined the financing as new investors. Existing investors, including Illumina Ventures and Sands Capital, also participated. The financing will support the continued commercial advancement of Alamar's precision proteomics platform.
"We deeply appreciate the continued support from our existing investors and are excited to welcome our new partners," said Dr. Yuling Luo, founder, chairman, and chief executive officer of Alamar. "Their confidence in our vision and strategy underscores the transformative potential of our work. This investment will enable us to accelerate innovation and continue to expand the reach of our platform, unlocking the full value of precision medicine and early disease detection."
Leadership and Board Expansion
Alamar also announced key additions to its executive leadership team and board of directors to support the company's continued growth and commitment to operational excellence.
To further strengthen its scientific leadership, Alamar welcomes Dr. Stephen Williams as Chief Scientific Officer. Steve brings more than three decades of experience in precision medicine and biomarker innovation. He most recently served as Chief Medical Officer at Standard BioTools and SomaLogic, and previously spent 18 years at Pfizer in senior leadership roles. A recognized leader in the scientific community, he has served on the NIH National Advisory Council for Biomedical Imaging and Bioengineering, helped launch the Alzheimer's Disease Neuroimaging Initiative, and co-founded the FDA-FNIH-PhRMA Biomarker Consortium.
Alamar has also appointed Rebecca Chambers and Dr. Frank Witney as directors to its board. Rebecca, Chief Financial Officer at Veracyte, brings deep financial and healthcare leadership experience from her current role as well as previous positions at Outset Medical, Illumina, Myriad Genetics and Life Technologies. Frank, an operating partner at Ampersand Capital Partners, adds over three decades of life sciences leadership experience, including serving as President and CEO of Affymetrix and Dionex Corporation, and currently sits on the boards of Revvity, Cerus Corporation, Standard BioTools, and several private companies.
"I am thrilled to welcome Steve to our leadership team, and Rebecca and Frank to our board of directors," said Dr. Yuling Luo. "Their deep expertise and diverse perspectives will be invaluable as we accelerate our mission to unleash the power of our Precision Proteomics platform, to enable broad impacts across health and disease. This is an exciting moment for Alamar, and we look forward to the impact their leadership will have on driving innovation and growth."
About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company dedicated to powering precision proteomics to enable the earliest detection of disease. Leveraging its proprietary NULISA™ technology and the ARGO™ HT System, Alamar's platform is designed to deliver ultra-high sensitivity and addresses key limitations of existing technologies to deliver precision proteomics. For more information, please visit alamarbio.com.
** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
Alamar Biosciences Announces Close of Oversubscribed Convertible Notes Financing and Expansion of Leadership Team
